Skip to main content
Top
Published in: Journal of Bioethical Inquiry 1/2017

01-03-2017 | Original Research

Debates about Conflict of Interest in Medicine: Deconstructing a Divided Discourse

Authors: Serena Purdy, Miles Little, Christopher Mayes, Wendy Lipworth

Published in: Journal of Bioethical Inquiry | Issue 1/2017

Login to get access

Abstract

The pharmaceutical industry plays an increasingly dominant role in healthcare, raising concerns about “conflicts of interest” (COI) on the part of the medical professionals who interact with the industry. However, there is considerable disagreement over the extent to which COI is a problem and how it should be managed. Participants in debates about COI have become entrenched in their views, which is both unproductive and deeply confusing for the majority of medical professionals trying to work in an increasingly commercialized environment. We used a modified meta-narrative review method to analyse debates about COI in the academic and grey literature. We found two Discourse Models: The Critical Discourse Model sees COI in health and biomedicine as a major problem that both can and should be addressed, while the Defensive Discourse Model argues that current efforts to control COIs are at best unnecessary and at worst harmful. Each model is underpinned by profoundly differing views about how society should be organized—in particular whether market forces should be encouraged or curtailed—and how the dangers associated with market forces should be managed. In order to make any headway, academics and policymakers must recognize that these debates are underpinned by profoundly differing worldviews.
Appendix
Available only for authorised users
Literature
go back to reference Abramson, J., and B. Starfield. 2005. The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidence-based medicine? Journal of the Amercian Board of Family Medicine 18(5): 414–418.CrossRef Abramson, J., and B. Starfield. 2005. The effect of conflict of interest on biomedical research and clinical practice guidelines: Can we trust the evidence in evidence-based medicine? Journal of the Amercian Board of Family Medicine 18(5): 414–418.CrossRef
go back to reference Angell, M. 2009. Drug companies & doctors: A story of corruption. The New York Review of Books 56(1): 8–12. Angell, M. 2009. Drug companies & doctors: A story of corruption. The New York Review of Books 56(1): 8–12.
go back to reference Barton, D., T. Stossel, and L. Stell. 2014. After 20 years, industry critics bury skeptics, despite empirical vacuum. International Journal of Clinical Practice 68(6): 666–673.CrossRefPubMed Barton, D., T. Stossel, and L. Stell. 2014. After 20 years, industry critics bury skeptics, despite empirical vacuum. International Journal of Clinical Practice 68(6): 666–673.CrossRefPubMed
go back to reference Bekelman, J., Y. Li, and C. Gross. 2003. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. Journal of the American Medical Association 289(4): 454–465.CrossRefPubMed Bekelman, J., Y. Li, and C. Gross. 2003. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. Journal of the American Medical Association 289(4): 454–465.CrossRefPubMed
go back to reference Brennan, T., D. Rothman, L. Blank, et al. 2006. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295(4): 429–433.CrossRefPubMed Brennan, T., D. Rothman, L. Blank, et al. 2006. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295(4): 429–433.CrossRefPubMed
go back to reference Ciociola, A., L. Cohen, P. Kulkarni, and The FDA-Related Matters Committee of the American College of Gastroenterology. 2014. How drugs are developed and approved by the FDA: Current process and future directions. The American Journal of Gastroenterology 109(5): 620–623.CrossRefPubMed Ciociola, A., L. Cohen, P. Kulkarni, and The FDA-Related Matters Committee of the American College of Gastroenterology. 2014. How drugs are developed and approved by the FDA: Current process and future directions. The American Journal of Gastroenterology 109(5): 620–623.CrossRefPubMed
go back to reference Citrome, L., J. Karagianis, G. Maguire, and A. Nierenberg. 2014. Pharmaism: A tale of two perspectives. International Journal of Clinical Practice 68(6): 659–661.CrossRefPubMed Citrome, L., J. Karagianis, G. Maguire, and A. Nierenberg. 2014. Pharmaism: A tale of two perspectives. International Journal of Clinical Practice 68(6): 659–661.CrossRefPubMed
go back to reference Cosgrove, L., A. Shaughnessy, E. Wheeler, et al. 2014. From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice 20(6): 809–812.CrossRefPubMed Cosgrove, L., A. Shaughnessy, E. Wheeler, et al. 2014. From caveat emptor to caveat venditor: time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice 20(6): 809–812.CrossRefPubMed
go back to reference Dana, J., and G. Loewenstein. 2003. A social science perspective on gifts to physicians from industry. JAMA 290(2): 252–255.CrossRefPubMed Dana, J., and G. Loewenstein. 2003. A social science perspective on gifts to physicians from industry. JAMA 290(2): 252–255.CrossRefPubMed
go back to reference DeMartino, J. 2012. The physician payment sunshine act. Journal of the National Comprehensive Cancer Network 10(3): 423–424. DeMartino, J. 2012. The physician payment sunshine act. Journal of the National Comprehensive Cancer Network 10(3): 423–424.
go back to reference Doran, E., I. Kerridge, P. McNeill, and D. Henry. 2006. Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry. Social Science & Medicine 62(6): 1510–1519.CrossRef Doran, E., I. Kerridge, P. McNeill, and D. Henry. 2006. Empirical uncertainty and moral contest: a qualitative analysis of the relationship between medical specialists and the pharmaceutical industry. Social Science & Medicine 62(6): 1510–1519.CrossRef
go back to reference Friedberg, M., B. Saffran, T. Stinson, W. Nelson, and C. Bennett. 1999. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282(15): 1453–1457.CrossRefPubMed Friedberg, M., B. Saffran, T. Stinson, W. Nelson, and C. Bennett. 1999. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282(15): 1453–1457.CrossRefPubMed
go back to reference Gee, J.P. 1999. An introduction to discourse analysis: Theory and method. London: Routledge. Gee, J.P. 1999. An introduction to discourse analysis: Theory and method. London: Routledge.
go back to reference Goldman, M., C. Compton, and B. Mittleman. 2013. Public–private partnerships as driving forces in the quest for innovative medicines. Clinical and Translational Medicine 2(1): 1–3.CrossRef Goldman, M., C. Compton, and B. Mittleman. 2013. Public–private partnerships as driving forces in the quest for innovative medicines. Clinical and Translational Medicine 2(1): 1–3.CrossRef
go back to reference Greenhalgh, T., G. Robert, F. Macfarlane, P. Bate, O. Kyriakidou, and R. Peacock. 2005. Storylines of research in diffusion of innovation: A meta-narrative approach to systematic review. Social Science & Medicine 61(2): 417–430.CrossRef Greenhalgh, T., G. Robert, F. Macfarlane, P. Bate, O. Kyriakidou, and R. Peacock. 2005. Storylines of research in diffusion of innovation: A meta-narrative approach to systematic review. Social Science & Medicine 61(2): 417–430.CrossRef
go back to reference Jakobsen, P., M.-W. Wang, and S. Nwaka. 2011. Innovative partnerships for drug discovery against neglected diseases. Plos Neglected Tropical Diseases 5(9): e1221.CrossRefPubMedPubMedCentral Jakobsen, P., M.-W. Wang, and S. Nwaka. 2011. Innovative partnerships for drug discovery against neglected diseases. Plos Neglected Tropical Diseases 5(9): e1221.CrossRefPubMedPubMedCentral
go back to reference Lemmens, T. 2004. Leopards in the temple: Restoring scientific integrity to the commercialized research scene. The Journal of Law, Medicine & Ethics 32(4): 641–657.CrossRef Lemmens, T. 2004. Leopards in the temple: Restoring scientific integrity to the commercialized research scene. The Journal of Law, Medicine & Ethics 32(4): 641–657.CrossRef
go back to reference Little, M., and W. Lipworth 2007. Focused discourse: An exploratory essay. Sydney: Centre for Values, Ethics and the Law in Medicine. Little, M., and W. Lipworth 2007. Focused discourse: An exploratory essay. Sydney: Centre for Values, Ethics and the Law in Medicine.
go back to reference Lo, B., and M. Field 2009. Conflict of interest in medical research, education, and practice. Washington (DC): National Academies Press. Lo, B., and M. Field 2009. Conflict of interest in medical research, education, and practice. Washington (DC): National Academies Press.
go back to reference Robertson, C., S. Rose, and A. Kesselheim. 2012. Effect of financial relationships on the behaviors of health care professionals: A review of the evidence. The Journal of Law, Medicine & Ethics 40(3): 452–466.CrossRef Robertson, C., S. Rose, and A. Kesselheim. 2012. Effect of financial relationships on the behaviors of health care professionals: A review of the evidence. The Journal of Law, Medicine & Ethics 40(3): 452–466.CrossRef
go back to reference Rodwin, M. 2012. Conflicts of interest, institutional corruption, and pharma: An agenda for reform. Journal of Law, Medicine and Ethics 40(3): 511–522.CrossRefPubMed Rodwin, M. 2012. Conflicts of interest, institutional corruption, and pharma: An agenda for reform. Journal of Law, Medicine and Ethics 40(3): 511–522.CrossRefPubMed
go back to reference Rosenbaum, L. 2015a. Beyond moral outrage—Weighing the trade-offs of COI regulation. New England Journal of Medicine 372(21): 2064–2068. Rosenbaum, L. 2015a. Beyond moral outrage—Weighing the trade-offs of COI regulation. New England Journal of Medicine 372(21): 2064–2068.
go back to reference ———. 2015b. Reconnecting the dots—Reinterpreting industry–physician relations. New England Journal of Medicine 372(19): 1860–1864. ———. 2015b. Reconnecting the dots—Reinterpreting industry–physician relations. New England Journal of Medicine 372(19): 1860–1864.
go back to reference ———. 2015c. Understanding bias—The case for careful study. New England Journal of Medicine 372(20): 1959–1963. ———. 2015c. Understanding bias—The case for careful study. New England Journal of Medicine 372(20): 1959–1963.
go back to reference Rothman, S., V. Raveis, A. Friedman, and D. Rothman. 2011. Health advocacy organizations and the pharmaceutical industry: An analysis of disclosure practices. American Journal of Public Health 101(4): 602–609.CrossRefPubMedPubMedCentral Rothman, S., V. Raveis, A. Friedman, and D. Rothman. 2011. Health advocacy organizations and the pharmaceutical industry: An analysis of disclosure practices. American Journal of Public Health 101(4): 602–609.CrossRefPubMedPubMedCentral
go back to reference Rothman, S., K. Brudney, W. Adair, and D. Rothman. 2013. Medical communication companies and industry grants. Journal of the American Medical Association 310(23): 2554–2558.CrossRefPubMed Rothman, S., K. Brudney, W. Adair, and D. Rothman. 2013. Medical communication companies and industry grants. Journal of the American Medical Association 310(23): 2554–2558.CrossRefPubMed
go back to reference Steinbrook, R., J. Kassirer, and M. Angell. 2015. Justifying conflicts of interest in medical journals: A very bad idea. British Medical Journal 350: h2942.CrossRefPubMed Steinbrook, R., J. Kassirer, and M. Angell. 2015. Justifying conflicts of interest in medical journals: A very bad idea. British Medical Journal 350: h2942.CrossRefPubMed
go back to reference Stell, L. 2010. Avoiding over-deterrence in managing physicians’ relationships with industry. American Journal of Bioethics 10(1): 27–29.CrossRefPubMed Stell, L. 2010. Avoiding over-deterrence in managing physicians’ relationships with industry. American Journal of Bioethics 10(1): 27–29.CrossRefPubMed
go back to reference Stossel, T., and L. Stell. 2011. Time to “walk the walk” about industry ties to enhance health. Nature Medicine 17(4): 437–438.CrossRefPubMed Stossel, T., and L. Stell. 2011. Time to “walk the walk” about industry ties to enhance health. Nature Medicine 17(4): 437–438.CrossRefPubMed
go back to reference Tierney, W., E. Meslin, and K. Kroenke. 2016. Industry support of medical research: Important opportunity or treacherous pitfall? Journal of General Internal Medicine 31(2): 228–233.CrossRefPubMed Tierney, W., E. Meslin, and K. Kroenke. 2016. Industry support of medical research: Important opportunity or treacherous pitfall? Journal of General Internal Medicine 31(2): 228–233.CrossRefPubMed
go back to reference Westphal, K.R. 2005. Dialectic. In The Edinburgh dictionary of continental philosophy, edited by J.L. Protevi, 147–148. Edinburgh: Edinburgh University Press. Westphal, K.R. 2005. Dialectic. In The Edinburgh dictionary of continental philosophy, edited by J.L. Protevi, 147–148. Edinburgh: Edinburgh University Press.
Metadata
Title
Debates about Conflict of Interest in Medicine: Deconstructing a Divided Discourse
Authors
Serena Purdy
Miles Little
Christopher Mayes
Wendy Lipworth
Publication date
01-03-2017
Publisher
Springer Netherlands
Published in
Journal of Bioethical Inquiry / Issue 1/2017
Print ISSN: 1176-7529
Electronic ISSN: 1872-4353
DOI
https://doi.org/10.1007/s11673-016-9764-7

Other articles of this Issue 1/2017

Journal of Bioethical Inquiry 1/2017 Go to the issue